Loading…
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-184M | $-244M | $-164M | -87.0% | -92.8% | - |
| 2024 | $135M | $-154M | $-122M | $-150M | -25.1% | 47.9% | - |
| 2023 | $91M | $-190M | $-147M | $-137M | -26.2% | 69.5% | - |
| 2022 | $54M | $-131M | $-117M | $-109M | -18.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 53.91 | 91.37 | 135.16 | 9.68 |
| Operating Expense | 185.46 | 282.41 | 289.72 | 194.24 |
| Operating Income | -131.56 | -191.04 | -154.56 | -184.56 |
| EBITDA | -130.81 | -190.11 | -153.67 | -183.66 |
| EBIT | -131.56 | -191.04 | -154.56 | -184.56 |
| Pretax Income | -125.61 | -160.48 | -128.93 | -200.83 |
| Tax Provision | -8.66 | -13.45 | -6.62 | 43.26 |
| Net Income | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income Common Stockholders | -116.95 | -147.03 | -122.31 | -244.09 |
| Total Expenses | 185.46 | 282.41 | 289.72 | 194.24 |
| Interest Income | 6.35 | 31.01 | 25.82 | 14.14 |
| Research And Development | 135.56 | 220.57 | 222.52 | 134.85 |
| Selling General And Administration | 49.90 | 61.84 | 67.20 | 59.39 |
| Normalized EBITDA | -130.42 | -189.65 | -153.48 | -153.26 |
| Normalized Income | -116.58 | -146.61 | -122.13 | -217.49 |
| Basic EPS | -2.47 | -2.76 | -2.27 | -4.53 |
| Diluted EPS | -2.47 | -2.76 | -2.27 | -4.53 |
| Tax Effect Of Unusual Items | -0.03 | -0.04 | -0.01 | -3.80 |
| Tax Rate For Calcs | 0.07 | 0.08 | 0.05 | 0.12 |
| Total Unusual Items | -0.40 | -0.46 | -0.18 | -30.41 |
| Total Unusual Items Excluding Goodwill | -0.40 | -0.46 | -0.18 | -30.41 |
| Net Income From Continuing Operation Net Minority Interest | -116.95 | -147.03 | -122.31 | -244.09 |
| Reconciled Depreciation | 0.74 | 0.93 | 0.89 | 0.90 |
| Net Interest Income | 6.35 | 31.01 | 25.82 | 14.14 |
| Net Income From Continuing And Discontinued Operation | -116.95 | -147.03 | -122.31 | -244.09 |
| Total Operating Income As Reported | -131.56 | -191.04 | -154.56 | -214.64 |
| Diluted Average Shares | 47.37 | 53.22 | 53.77 | 53.83 |
| Basic Average Shares | 47.37 | 53.22 | 53.77 | 53.83 |
| Diluted NI Availto Com Stockholders | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income Including Noncontrolling Interests | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income Continuous Operations | -116.95 | -147.03 | -122.31 | -244.09 |
| Other Income Expense | -0.40 | -0.46 | -0.18 | -30.41 |
| Other Non Operating Income Expenses | -0.40 | -0.46 | 0 | 0 |
| Special Income Charges | 0 | 0 | 0 | -30.08 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 30.08 |
| Gain On Sale Of Security | -0.40 | -0.46 | -0.18 | -0.33 |
| Net Non Operating Interest Income Expense | 6.35 | 31.01 | 25.82 | 14.14 |
| Interest Income Non Operating | 6.35 | 31.01 | 25.82 | 14.14 |
| General And Administrative Expense | 49.90 | 61.84 | 67.20 | 59.39 |
| Other Gand A | 49.90 | 61.84 | 67.20 | 59.39 |
| Operating Revenue | 53.91 | 91.37 | 135.16 | 9.68 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Prothena Corporation plcthis co. | PRTA | $585M | - | 2.09 | -87.0% | -1.56 |
| Arvinas, Inc. | ARVN | $628M | - | 1.44 | -18.6% | 0.43 |
| Aclaris Therapeutics, Inc. | ACRS | $624M | - | 5.23 | -63.0% | -6.08 |
| CorMedix Inc. | CRMD | $591M | 3.67 | 1.46 | 40.2% | 3.38 |
| Anteris Technologies Global Corp. | AVR | $574M |
| - |
| -2950.00 |
| - |
| -6.11 |
| Zevra Therapeutics, Inc. | ZVRA | $572M | 7.16 | 3.56 | 53.8% | -2457.74 |
| Phreesia, Inc. | PHR | $569M | 234.25 | 1.69 | 0.7% | 29.02 |
| NeuroPace, Inc. | NPCE | $562M | - | 29.17 | -112.8% | -35.19 |
| Rigel Pharmaceuticals, Inc. | RIGL | $540M | 1.50 | 1.37 | 93.8% | 3.43 |
| Peer Median | - | 5.41 | 1.57 | 0.7% | -2.83 | |